205 related articles for article (PubMed ID: 26942564)
1. Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3.
Wang H; Xie B; Kong Y; Tao Y; Yang G; Gao M; Xu H; Zhan F; Shi J; Zhang Y; Wu X
Oncotarget; 2016 Apr; 7(14):18638-50. PubMed ID: 26942564
[TBL] [Abstract][Full Text] [Related]
2. RPS27a promotes proliferation, regulates cell cycle progression and inhibits apoptosis of leukemia cells.
Wang H; Yu J; Zhang L; Xiong Y; Chen S; Xing H; Tian Z; Tang K; Wei H; Rao Q; Wang M; Wang J
Biochem Biophys Res Commun; 2014 Apr; 446(4):1204-10. PubMed ID: 24680683
[TBL] [Abstract][Full Text] [Related]
3. Re-Expression of Bone Marrow Proteoglycan-2 by 5-Azacytidine is associated with STAT3 Inactivation and Sensitivity Response to Imatinib in Resistant CML Cells.
Al-Jamal HAN; Johan MF; Mat Jusoh SA; Ismail I; Wan Taib WR
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1585-1590. PubMed ID: 29936783
[TBL] [Abstract][Full Text] [Related]
4. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
5. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
Mencalha AL; Corrêa S; Salles D; Du Rocher B; Santiago MF; Abdelhay E
BMC Cancer; 2014 Nov; 14():866. PubMed ID: 25417721
[TBL] [Abstract][Full Text] [Related]
7. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.
Dong B; Liang Z; Chen Z; Li B; Zheng L; Yang J; Zhou H; Qu L
Sci China Life Sci; 2018 Sep; 61(9):999-1009. PubMed ID: 30054832
[TBL] [Abstract][Full Text] [Related]
8. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
Li X; Miao H; Zhang Y; Li W; Li Z; Zhou Y; Zhao L; Guo Q
Arch Toxicol; 2015 Jan; 89(1):121-36. PubMed ID: 24671465
[TBL] [Abstract][Full Text] [Related]
10. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
[TBL] [Abstract][Full Text] [Related]
11. CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR-ABL-positive cells.
Huang SY; Liu YH; Chen YJ; Yeh YY; Huang HM
J Cell Physiol; 2018 Sep; 233(9):7467-7479. PubMed ID: 29663362
[TBL] [Abstract][Full Text] [Related]
12. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.
Wang H; Li Q; Tang S; Li M; Feng A; Qin L; Liu Z; Wang X
Hematology; 2017 May; 22(4):208-216. PubMed ID: 27875938
[TBL] [Abstract][Full Text] [Related]
13. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS
Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
15. Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia.
Cheng R; Huang Y; Fang Y; Wang Q; Yan M; Ge Y
Pharm Biol; 2021 Dec; 59(1):893-903. PubMed ID: 34214017
[TBL] [Abstract][Full Text] [Related]
16. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
17. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W
Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells.
Coppo P; Flamant S; De Mas V; Jarrier P; Guillier M; Bonnet ML; Lacout C; Guilhot F; Vainchenker W; Turhan AG
Br J Haematol; 2006 Jul; 134(2):171-9. PubMed ID: 16846476
[TBL] [Abstract][Full Text] [Related]
19. Expression of the ETS transcription factor GABPα is positively correlated to the BCR-ABL1/ABL1 ratio in CML patients and affects imatinib sensitivity in vitro.
Manukjan G; Ripperger T; Santer L; von Neuhoff N; Ganser A; Schambach A; Schlegelberger B; Steinemann D
Exp Hematol; 2015 Oct; 43(10):880-90. PubMed ID: 26072332
[TBL] [Abstract][Full Text] [Related]
20. TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/β‑catenin/TCF7/ABC transporter signaling axis.
Zhang H; Wang Y; Yang H; Huang Z; Wang X; Feng W
Oncol Rep; 2021 Feb; 45(2):557-568. PubMed ID: 33416164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]